Cytek Biosciences Inc (CTKB)vsMerck & Company Inc (MRK)
CTKB
Cytek Biosciences Inc
$4.56
+2.70%
HEALTHCARE · Cap: $565.62M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 32165% more annual revenue ($65.01B vs $201.49M). MRK leads profitability with a 28.1% profit margin vs -33.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
CTKB
Hold41
out of 100
Grade: D
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.2%
Fair Value
$8.94
Current Price
$4.56
$4.38 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.28 — expect wider price swings.
CTKB is growing revenue faster at 8.1% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 41/100), backed by strong 28.1% margins. CTKB offers better value entry with a 51.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a leading innovator in multi-parameter flow cytometry, delivering cutting-edge cell analysis solutions that are vital for advancements in the life sciences sector. Specializing in technologies that enhance cellular analyses, Cytek plays a significant role in research areas such as immunology, cancer diagnostics, and drug development. The company's commitment to innovation and exceptional customer service has established it as a key player in the biotechnology industry, effectively meeting the increasing demand for accurate and precise cell analysis tools. With a diverse product portfolio and a strong market presence, Cytek continues to push the boundaries of cell biology research, fostering breakthroughs that can transform healthcare outcomes.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?